These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11969409)

  • 41. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
    Llinàs-Brunet M; Bailey M; Déziel R; Fazal G; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2719-24. PubMed ID: 9873610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
    J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
    Dimasi N; Martin F; Volpari C; Brunetti M; Biasiol G; Altamura S; Cortese R; De Francesco R; Steinkühler C; Sollazzo M
    J Virol; 1997 Oct; 71(10):7461-9. PubMed ID: 9311825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease.
    Skoreński M; Pachota M; Pyrć K; Sieńczyk M; Oleksyszyn J
    Antiviral Res; 2017 Aug; 144():286-298. PubMed ID: 28673801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase.
    Shiryaev SA; Cheltsov AV; Strongin AY
    PLoS One; 2012; 7(7):e40029. PubMed ID: 22768327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A scintillation proximity active site binding assay for the hepatitis C virus serine protease.
    Steinkühler C; Biasiol G; Cerretani M; Di Renzo L; Brunetti M; Ingallinella P; De Francesco R; Altamura S
    Anal Biochem; 2002 Aug; 307(1):99-104. PubMed ID: 12137785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization.
    Koch U; Biasiol G; Brunetti M; Fattori D; Pallaoro M; Steinkühler C
    Biochemistry; 2001 Jan; 40(3):631-40. PubMed ID: 11170379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.
    Tong X; Guo Z; Wright-Minogue J; Xia E; Prongay A; Madison V; Qiu P; Venkatraman S; Velazquez F; Njoroge FG; Malcolm BA
    Biochemistry; 2006 Feb; 45(5):1353-61. PubMed ID: 16445277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design of selective eglin inhibitors of HCV NS3 proteinase.
    Martin F; Dimasi N; Volpari C; Perrera C; Di Marco S; Brunetti M; Steinkühler C; De Francesco R; Sollazzo M
    Biochemistry; 1998 Aug; 37(33):11459-68. PubMed ID: 9708981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex.
    Brass V; Berke JM; Montserret R; Blum HE; Penin F; Moradpour D
    Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14545-50. PubMed ID: 18799730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
    Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease.
    D'Souza ED; Grace K; Sangar DV; Rowlands DJ; Clarke BE
    J Gen Virol; 1995 Jul; 76 ( Pt 7)():1729-36. PubMed ID: 9049378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
    Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.